Jefferies cuts Solventum stock price target to $34 on de-rating
Jefferies reduced its price target for Solventum Corp. (NYSE:SOLV) to $34 from $43, citing a sector selloff, while maintaining a Buy rating. The firm raised its EBITDA estimates by 7% to 13%, noting the company's $8.9 billion backlog and strong project execution. Solventum's Q2 earnings beat expectations with $2.55 EPS and $2.2B revenue, leading to an improved outlook. Stifel reiterated its Buy rating with a $100 target, adjusting growth estimates for the MedSurg division.
How this was made
The 30-second read
Why it matters
The mixed analyst coverage creates short‑term volatility, with the target cut likely prompting downside pressure.
Market read
SOLV's stock may experience near‑term price pressure due to the new lower target despite recent earnings strength.
What to watch
The 7% EBITDA estimate increase and low valuation multiples relative to peers may be undervalued.
Background
Jefferies lowered its price target for SOLV while Stifel kept a $100 target, reflecting divergent analyst views.
Ticker impact
Jefferies cut its price target on Solventum Corp. (SOLV) to $34 from $43 and highlighted recent earnings beat.
likely pressure as the market prices in the lower target
Target cut combined with a modest earnings beat suggests limited upside and may trigger sell‑offs.
Market effects
The downgrade may weigh on other engineering‑procurement‑construction peers.
Limited to U.S. equities; no broader regional effect.
Minimal global impact beyond the sector.
Counterpoint
Despite the target cut, the earnings beat and strong backlog could support a rebound.
Key entities
- AnalystJefferies
Research firm that cut SOLV price target to $34.
- AnalystStifel
Maintained a $100 price target for SOLV.
